Position in VCEL
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$640,344
-$577,723 QoQ
Shares Held
14,393
-50.1% QoQ
Ownership
0.028%
of shares outstanding
% of Portfolio
0.33%
of 13F equity value
Holder Rank
#163
of 315 holders
Holding Since
Mar 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VCEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Jackson Creek Investment Advisors LLC holds $9,711,003 across 17 Biotechnology names. VCEL ranks #6 (6.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
6,037 | $1,908,235 | |
| 2 | TVTX |
Travere Therapeutics, Inc.
|
30,801 | $1,749,804 | |
| 3 | TBPH |
Theravance Biopharma, Inc.
|
85,508 | $1,453,636 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
4,740 | $1,142,197 | |
| 5 | RPRX |
Royalty Pharma plc
|
12,743 | $714,500 | |
| 6 | VCEL |
Vericel Corp
This page
|
14,393 | $640,344 | |
| 7 | WVE |
Wave Life Sciences, Inc.
|
92,662 | $538,366 | |
| 8 | JANX |
Janux Therapeutics, Inc.
|
34,719 | $533,283 |
All Filings in VCEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $640,344 | 14,393 | Shares | Sole | 2026-08-10 | |
| 2024-09-30 | $1,218,067 | 28,830 | Shares | Sole | 2024-11-04 | |
| 2024-06-30 | $1,026,381 | 22,371 | Shares | Sole | 2024-08-02 | |
| 2024-03-31 | $1,165,352 | 22,402 | Shares | Sole | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||